Atreca – Turning the Current Cancer Therapeutic Discovery Paradigm on its Head

John Orwin, President and CEO of Atreca, a biopharmaceutical company, discusses their drug Discovery Platform and how they are thinking differently about the fight against cancer and their part in helping to fuel the next generation of antibody-based advancements in cancer treatment. He also talks about what’s on the horizon in 2021 for Atreca’s lead candidate ATRC-101 and their additional pipeline developments.

John Orwin, President and CEO of Atreca. John Orwin has more than 25 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer, Genentech, and most recently Relypsa. During Mr. Orwin’s tenure at Relypsa, the company launched and commercialized its lead candidate, Patiromer (US brand name Veltassa®), and was acquired by Galenica (ViforPharma) in a transaction worth over $1.5 billion. Prior to Relypsa, he served as Chief Executive Officer and a member of the Board of Directors of Affymax. Previously, Mr. Orwin was Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhône-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University.